Self Titration With Apidra to Reach Target Study (START)
Primary Purpose
Diabetes Mellitus, Type 2
Status
Completed
Phase
Phase 4
Locations
Canada
Study Type
Interventional
Intervention
insulin glargine
Apidra (insulin glulisine)
Sponsored by

About this trial
This is an interventional treatment trial for Diabetes Mellitus, Type 2
Eligibility Criteria
Inclusion criteria:
Run-in phase:
- T2DM
- Treated for at least 3 months with a basal insulin (insulin glargine, NPH, detemir) +/- oral antidiabetic drugs (OADs) with an HbA1c >7.0% or insulin naive (2-3 OADs) with an HbA1c >=7.8% (historic HbA1c result up to 3 months of screening is acceptable)
Randomized treatment phase:
- Completed run-in phase
- HbA1c >7.0% and >= 1 episode of confirmed nocturnal hypoglycemia (BG <4.0 mmol/L) or >= 2 measurements of FG <=6.0 mmol/L within the previous week Patients who completed the run-in phase with HbA1c >7.0% and did not meet the randomization criteria will continue titrating insulin glargine and be followed until the end of study.
Exclusion Criteria:
- No food intake before lunch (noon)
- Unstable diet intake or significant changes to current diet regimen
- Nightshift worker
- Type 1 Diabetes Mellitus
- Subjects unwilling to inject insulin or perform self-monitoring blood glucose
- Pregnant, alcohol or drug abuse
- Active cancer or any other disease or condition which in the opinion of the investigator would make the subject unsuitable for participation in the study
- Any clinical significant laboratory findings that in the judgment of the investigator would preclude safe completion of the study
- Known allergies to study drugs
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Sites / Locations
- Sanofi-Aventis Administrative Office
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Experimental
Arm Label
1
2
Arm Description
12-week run-in phase with Glargine +/- OADs followed by 24-week treatment phase with glulisine (AM) + glargine ; health care professional-managed
12-week run-in phase with Glargine +/- OADs followed by 24-week treatment phase with glulisine (AM) + glargine ; patient-managed
Outcomes
Primary Outcome Measures
Percentage of subjects reaching target HbA1c <=7.0% without severe hypoglycemia
Secondary Outcome Measures
Change in HbA1c, FG, and 7-point glucose profile
Change in weight
Incidence of hypoglycemia
Treatment satisfaction (DTSQ for patient )
Adherence with the patient-managed monitoring algorithm
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01013571
Brief Title
Self Titration With Apidra to Reach Target Study (START)
Official Title
A Canadian, Phase IV, Multicenter, Comparative, Open-label Study Evaluating 2 Approaches of Blood Glucose Monitoring and Insulin Titration (Patient-managed vs Health Care Professional) in T2DM Patients While Receiving the Addition of 1 Injection of Insulin Glulisine at Breakfast Following Optimization of Insulin Glargine
Study Type
Interventional
2. Study Status
Record Verification Date
March 2012
Overall Recruitment Status
Completed
Study Start Date
October 2009 (undefined)
Primary Completion Date
January 2012 (Actual)
Study Completion Date
January 2012 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Sanofi
4. Oversight
5. Study Description
Brief Summary
Primary Objective:
The primary objective of this study is to demonstrate non-inferiority of a patient-managed titration algorithm (including blood glucose monitoring) for the addition of a single dose of insulin glulisine at breakfast in Canadian patients with inadequately controlled T2DM after optimization of basal insulin, compared with an HCP-managed titration algorithm. The primary endpoint for assessment of this objective is the percent of patients reaching a target HbA1c <=7.0% without severe hypoglycemia at the end of the study.
Secondary Objective:
Secondary objectives of the study are to compare the effect of the two different insulin glulisine titration algorithms (patient-managed versus HCP-managed) on the following:
change in HbA1c, FG, and 7-point glucose profile at Week 24 and Week 36
satisfaction with treatment (DTSQc for patient and questionnaire for HCP) at Week 36
change in weight at Week 24 and Week 36
incidence of hypoglycemia
insulin doses
resource utilization (rural/urban, blood glucose meter test strips, lancets, HCP visits, telephone calls, and hospitalizations)
adherence with the patient-managed monitoring algorithm
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Type 2
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
493 (Actual)
8. Arms, Groups, and Interventions
Arm Title
1
Arm Type
Experimental
Arm Description
12-week run-in phase with Glargine +/- OADs followed by 24-week treatment phase with glulisine (AM) + glargine ; health care professional-managed
Arm Title
2
Arm Type
Experimental
Arm Description
12-week run-in phase with Glargine +/- OADs followed by 24-week treatment phase with glulisine (AM) + glargine ; patient-managed
Intervention Type
Drug
Intervention Name(s)
insulin glargine
Intervention Description
pre-filled disposable pen, in package of 5.
Intervention Type
Drug
Intervention Name(s)
Apidra (insulin glulisine)
Intervention Description
pre-filled disposable pen, in package of 5
Primary Outcome Measure Information:
Title
Percentage of subjects reaching target HbA1c <=7.0% without severe hypoglycemia
Time Frame
at week 36 (end of study)
Secondary Outcome Measure Information:
Title
Change in HbA1c, FG, and 7-point glucose profile
Time Frame
from Week 12 (randomization) to Week 24 and Week 36
Title
Change in weight
Time Frame
from Week 12 to Week 24 and to Week 36
Title
Incidence of hypoglycemia
Time Frame
Week 12 , Week 24 and Week 36
Title
Treatment satisfaction (DTSQ for patient )
Time Frame
from Week 12 to Week 36
Title
Adherence with the patient-managed monitoring algorithm
Time Frame
Week 12 , Week 24 and Week 36
10. Eligibility
Sex
All
Minimum Age & Unit of Time
30 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion criteria:
Run-in phase:
T2DM
Treated for at least 3 months with a basal insulin (insulin glargine, NPH, detemir) +/- oral antidiabetic drugs (OADs) with an HbA1c >7.0% or insulin naive (2-3 OADs) with an HbA1c >=7.8% (historic HbA1c result up to 3 months of screening is acceptable)
Randomized treatment phase:
Completed run-in phase
HbA1c >7.0% and >= 1 episode of confirmed nocturnal hypoglycemia (BG <4.0 mmol/L) or >= 2 measurements of FG <=6.0 mmol/L within the previous week Patients who completed the run-in phase with HbA1c >7.0% and did not meet the randomization criteria will continue titrating insulin glargine and be followed until the end of study.
Exclusion Criteria:
No food intake before lunch (noon)
Unstable diet intake or significant changes to current diet regimen
Nightshift worker
Type 1 Diabetes Mellitus
Subjects unwilling to inject insulin or perform self-monitoring blood glucose
Pregnant, alcohol or drug abuse
Active cancer or any other disease or condition which in the opinion of the investigator would make the subject unsuitable for participation in the study
Any clinical significant laboratory findings that in the judgment of the investigator would preclude safe completion of the study
Known allergies to study drugs
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Clinical Sciences & Operations
Organizational Affiliation
Sanofi
Official's Role
Study Director
Facility Information:
Facility Name
Sanofi-Aventis Administrative Office
City
Laval
Country
Canada
12. IPD Sharing Statement
Citations:
PubMed Identifier
24170757
Citation
Harris SB, Yale JF, Berard L, Stewart J, Abbaszadeh B, Webster-Bogaert S, Gerstein HC. Does a patient-managed insulin intensification strategy with insulin glargine and insulin glulisine provide similar glycemic control as a physician-managed strategy? Results of the START (Self-Titration With Apidra to Reach Target) Study: a randomized noninferiority trial. Diabetes Care. 2014;37(3):604-10. doi: 10.2337/dc13-1636. Epub 2013 Oct 29.
Results Reference
derived
Learn more about this trial
Self Titration With Apidra to Reach Target Study (START)
We'll reach out to this number within 24 hrs